The startup develops nucleic acid, gene, and cell therapies aimed at treating incurable diseases such as cancer, drug-resistant infections, and Alzheimer's disease. By focusing on reducing the side effects of these treatments, the company enhances the quality of life for patients and their families.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for incurable diseases like cancer, drug-resistant infections, and Alzheimer's often have severe side effects, diminishing the quality of life for patients and their families. The lack of targeted therapies results in systemic toxicity, limiting the dosage and effectiveness of treatments.
Solution
This startup is developing nucleic acid, gene, and cell therapies designed to target the underlying causes of incurable diseases while minimizing off-target effects. Their approach focuses on precision delivery mechanisms to ensure therapeutic agents reach diseased cells and tissues, sparing healthy ones. By reducing systemic toxicity, the company aims to improve patient outcomes and enhance their overall well-being during treatment. The therapies are engineered to modulate gene expression, stimulate immune responses, or replace damaged cells, offering potential cures or long-term disease management.
Target Audience
The primary target audience includes patients suffering from incurable diseases such as cancer, drug-resistant infections, and Alzheimer's disease, as well as the healthcare providers who treat them.
Features
- Nucleic acid therapies designed for targeted gene silencing or activation
- Gene editing technologies for precise correction of disease-causing mutations
- Cell therapies utilizing engineered immune cells to target and eliminate cancer cells
- Targeted delivery systems to enhance therapeutic efficacy and reduce side effects